Sharemaestro Newsreel

ANI Pharmaceuticals (ANIP) SVP Ori Gutwerg sells 3,162 shares at $77

Ori Gutwerg, Senior Vice President of Generics at ANI Pharmaceuticals Inc. (ANIP), sold 3,162 shares of common stock at $77.00 per share on August 10, 2026. Following this transaction, Gutwerg directly holds 75,534 shares of the company's common stock. The sale, valued at $243,000, …

TherapeuticsMD Q2 2026 Earnings: License Revenue and Net Income Decline

TherapeuticsMD reported a decline in Q2 2026 license revenue and a significant drop in net income, while operating expenses slightly increased. The company continues to rely heavily on licensee performance and milestone payments, with an IMVEXXY milestone expected in Q3 2026. TherapeuticsMD is also …

Harrow (HROW) Stock Grapples With Losses Despite Double Digit Revenue Growth

Viatris Inc. (VTRS) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Viatris Inc. (VTRS) stock, including its current price, dividend information, and a collection of recent news articles. The news highlights Viatris's Q2 earnings performance, strategic moves like selling Tyrvaya, and analyst insights on its valuation …

Takeda Pharmaceutical (TSE:4502) Wins ORZEYFUL Approval, Where Does Fair Value Sit?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after U.S. regulators approved ORZEYFUL for adult narcolepsy type 1, and the company also issued new impairment …

Aquestive Therapeutics Q2 Loss Widens, Revenue Rises

Aquestive Therapeutics reported a wider net loss in Q2 compared to the previous year, despite an increase in total revenue. The company also updated its full-year 2026 outlook, anticipating total revenue to be between $58 million and $62 million, with non-GAAP adjusted EBITDA expected …

Hims & Hers (HIMS) Stock Rally Meets Margin Pressure And GAAP Loss

Hi*Ball® Energy Powers into the English Football League with Wolverhampton Wanderers Partnership

Hi*Ball Energy, a zero-sugar sparkling energy brand from Tilray Brands, has announced a significant partnership with Wolverhampton Wanderers Football Club (Wolves). This agreement makes Hi*Ball the Club's Official Energy Drink Partner for the upcoming EFL Championship season, marking its first sports partnership in the …

Is Amylyx (AMLX) Quietly Rewriting Its R&D Risk‑Reward Profile As Losses Deepen Without Revenue?

Amylyx Pharmaceuticals (AMLX) reported a widening net loss in Q2 2026, reaching US$43.42 million, and a six-month net loss of US$84.71 million, even though basic loss per share slightly narrowed. This indicates increasing development costs for its pipeline without corresponding revenue. The company's investment …

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Brinker International (EAT [https://seekingalpha.com/symbol/EAT]) * Amcor plc (AMCR [https://seekingalpha.com/symbol/AMCR]) * Jumia Technologies AG (JMIA [https://seekingalpha.com/symbol/JMIA]) Other earnings slated for release before Wednesday's …

Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 8,180 Shares

Amphastar Pharmaceuticals' CFO, William Peters, sold 8,180 shares of the company's stock for a total of $183,886.40, reducing his holdings by 4.52%. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings, beating analyst estimates for both …

Did FDA’s Positive Reykjavik Plant Outcome Just Shift Alvotech’s (ALVO) Biosimilar Expansion Narrative?

Alvotech recently announced that the FDA closed its inspection of the company's Reykjavik facility with a Voluntary Action Indicated classification, addressing previous observations and allowing the advancement of multiple Biologics License Applications. This positive regulatory outcome reduces near-term overhang and supports the company's efforts …

TherapeuticsMD Q2 Results: Net Income Falls 70% To $164 Thousand

TherapeuticsMD (NASDAQ: TXMD) reported a significant decline in its Q2 2026 financial performance, with EPS dropping 80% to $0.01 and net income falling 70% to $164 thousand. This was primarily due to decreased license revenues and a modest increase in operating expenses. The company …

Tilray Brands Inc. stock rises Tuesday, outperforms market

Tilray Brands Inc. (TLRY) stock rose 8.14% on Tuesday to $4.78, outperforming the broader market as both the NASDAQ Composite and Dow Jones Industrial Average declined. Despite the gain, the stock closed 79.40% below its 52-week high of $23.20, achieved on October 9th.

Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Pacira BioSciences' stock (PCRX) fell 7.1% despite advancing its PCRX-201 gene therapy for knee osteoarthritis into Phase 2 following positive two-year Phase 1 data. The company also announced revised full-year revenue expectations of US$735 million to US$760 million, down from prior guidance, but reported …

TherapeuticsMD, Inc. Q2 2026: Revenue $869K, EPS $0.01— 10-Q Summary

TherapeuticsMD, Inc. reported its Q2 2026 financial results, with revenue of $869K and diluted EPS of $0.01, showing a decrease from the prior year. The company has completed its transformation into a pharmaceutical royalty company, with revenue primarily derived from royalty and milestone payments …

Amphastar (AMPH) CFO exercises options and sells 8,180 shares in 10b5-1 trade

Amphastar Pharmaceuticals' CFO, William J. Peters, exercised 5,053 employee stock options at $19.79 per share and subsequently sold 8,180 shares of common stock at $22.48 per share on August 7, 2026. This sale was conducted under a Rule 10b5-1 trading plan adopted on March …

Aquestive Therapeutics: Q2 Earnings Snapshot

This article provides a brief "Q2 Earnings Snapshot" for Aquestive Therapeutics. It is a very short piece, indicating that the company's Q2 earnings were reported.

Eton Pharmaceuticals Inc expected to post earnings of 11 cents a share - Earnings Preview

Eton Pharmaceuticals Inc is projected to report earnings of 11 cents per share. This information comes from an earnings preview. The full article is available on TradingView, which provides access to content from various news sources.

TherapeuticsMD Q2 2026 License Revenue Falls to $869000

TherapeuticsMD (TXMD) reported a decline in Q2 2026 license revenue to $869,000 from $952,000 in the prior year, with net income from continuing operations also falling to $164,000. The company's operating expenses were $1.7 million, and it held $9.2 million in cash and cash …

Is Hims The Next Big Name In Peptides? Shares Topple Despite Sales Beat.

Hims stock toppled Tuesday. Analysts are watching the telehealth giant's move closer to the peptide segment. Continue Reading

TherapeuticsMD (TXMD) posts Q2 2026 update and weighs strategic alternatives

TherapeuticsMD (TXMD) reported its Q2 2026 financial results, revealing a net income of $164 thousand and license revenue of $869 thousand. The company has fully transitioned into a pharmaceutical royalty company, collecting royalties from licensees, and is actively exploring strategic alternatives including potential acquisition …

TherapeuticsMD to Recognize About $365K IMVEXXY Milestone in Q3

TherapeuticsMD (NASDAQ: TXMD) reported second-quarter 2026 financial results, with net income from continuing operations totaling $164 thousand. The company expects to recognize approximately $365K (CAD 500K) in revenue during the third quarter of 2026 from an IMVEXXY sales milestone achieved by Knight Therapeutics Inc. …

TXMD: Q2 2026 saw lower net income and license revenue, with strategic alternatives under evaluation

TherapeuticsMD (TXMD) experienced a decline in net income and license revenue in Q2 2026, alongside a slight increase in operating expenses. The company is actively exploring strategic alternatives due to ongoing risks from licensee performance, litigation, and market volatility. This information is based on …

Trade Desk, Papa John's, Emergent BioSolutions Hit 52-Week Lows as Weak Results Trigger Analyst Downgrades

Trade Desk, Papa John's, and Emergent BioSolutions all hit 52-week lows following disappointing quarterly results and subsequent analyst downgrades. Trade Desk faced a significant downgrade after missing revenue estimates and providing weak guidance, while Papa John's experienced a revenue decline despite an earnings beat. …

US marijuana MSO Curaleaf plots $272 million hostile takeover of Aurora Cannabis

US-based cannabis multistate operator Curaleaf Holdings is pursuing a hostile takeover of Canadian licensed producer Aurora Cannabis, offering $4 per share in a mix of stock and cash, totaling $272 million. This move comes after Aurora's leadership reportedly declined to discuss a deal, prompting …

Kamada Q2 2026 Earnings Preview

* Kamada (KMDA [https://seekingalpha.com/symbol/KMDA]) is scheduled to announce Q2 earnings results on Wednesday, August 12th, before market open. * The consensus EPS Estimate is $0.11 [https://seekingalpha.com/symbol/KMDA/earnings/estimates] (-15.4% Y/Y) and the consensus Revenue Estimate is $49.1M (+9.7% Y/Y). * Over the last 2 years, KMDA …

HROW Reiterated by BTIG -- Price Target Maintained at $63

BTIG has reiterated its "Buy" rating for Harrow Inc (HROW), maintaining a price target of $63.00, which suggests the stock is currently undervalued by approximately 12.8% according to GuruFocus's GF Value™ of $44.53. Despite being unprofitable with a high forward P/E, the company shows …

Aquestive Plans to Take Epi Film Back to FDA with Positive Data

Aquestive Therapeutics plans to resubmit its drug application for Anaphylm, an oral dissolving film for severe allergic reactions, to the FDA this fall. This follows the completion of two additional studies requested by the FDA, which have yielded positive results regarding revised packaging, ease …

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

Rocket Pharmaceuticals RCKT reported earnings of $1.08 per share (including certain one-time items) in the second quarter of 2026 in contrast to a loss of 62 cents per share incurred in the year-ago quarter. The Zacks Consensus Estimate for the company's bottom line was …

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

Axsome Therapeutics AXSM incurred a loss of 99 cents per share in the second quarter of 2026, which was in line with the Zacks Consensus Estimate. The company had reported a loss of 97 cents per share in the year-ago quarter. Axsome's total revenues …

EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions

SueWallSt, powered by Levi & Korsinsky LLP, has announced an investigation into potential securities law violations by Emergent BioSolutions (NYSE: EBS). This follows Emergent BioSolutions lowering its FY2026 adjusted EBITDA guidance and recording a significant non-cash NARCAN impairment due to increased competition and pricing …

Hims & Hers earnings analysis: questions answered and next catalysts

Haleon plc (HLN) files Form 6-K on cash tender offer for 2027 3.375% notes

Haleon plc has filed a Form 6-K announcing a cash tender offer for its outstanding 2027 3.375% Fixed Rate Notes, as detailed in an exhibit dated August 11, 2026. This filing serves to inform U.S. investors about the debt-related transaction. The offer targets debt …

Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7.1% - Here's Why

Aquestive Therapeutics (NASDAQ:AQST) saw its shares rise 7.1% to $4.595, with a market capitalization of approximately $574 million. The company's stock holds a consensus "Buy" rating from analysts with an average price target of $8.50, driven by its recent beat on quarterly earnings expectations. …